Male breast cancer: a Sri Lankan case report and review of literature

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2022-03-01 DOI:10.2217/bmt-2021-0014

Sanura Malinda Pallegoda Vithana, L. Chathuranga, S. Jayasinghe, Edippuli Arachchige Don Udayakumara

引用次数: 2

Abstract

Male breast cancers account for 1% of worldwide breast malignancies and are on the rise. Sri Lankan accounts are limited due to lack of healthcare seeking behavior among men. A 63-year-old male presented with a right sided hard breast lump and a Breast Imaging Reporting and Database System score 5 lesion with axillary lymph node metastasis was observed on ultrasonography. Core biopsy revealed invasive ductal breast cancer. Tumor staging revealed a T2N1M0 cancer for which mastectomy with level 2 axillary clearance was performed followed by radiotherapy and systemic therapy. Male breast cancer even though similar to female breast cancers have important distinctions with regard to molecular biology, lymphatic metastasis and age of presentation. Management; however, still relies on studies based on the female counterpart.

查看原文本刊更多论文

男性乳腺癌:斯里兰卡病例报告及文献回顾

男性乳腺癌占全球乳腺恶性肿瘤的1%，并且呈上升趋势。由于男性缺乏寻求医疗保健的行为，斯里兰卡的账户有限。男性，63岁，右侧硬乳房肿块，超声检查为乳腺影像学报告和数据库系统评分5分病变伴腋窝淋巴结转移。核心活检显示浸润性导管性乳腺癌。肿瘤分期显示为T2N1M0癌，进行乳房切除术并2级腋窝清除，然后进行放疗和全身治疗。男性乳腺癌虽然与女性乳腺癌相似但在分子生物学，淋巴转移和发病年龄方面有着重要的区别。管理;然而，仍然依赖于基于女性对应物的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.